GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VGI Health Technology Ltd (XNEC:VTL) » Definitions » Other Current Receivables

VGI Health Technology (XNEC:VTL) Other Current Receivables : A$0.00 Mil (As of . 20)


View and export this data going back to 2021. Start your Free Trial

What is VGI Health Technology Other Current Receivables?

VGI Health Technology's Other Current Receivables for the quarter that ended in . 20 was A$0.00 Mil.


VGI Health Technology Other Current Receivables Historical Data

The historical data trend for VGI Health Technology's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VGI Health Technology Other Current Receivables Chart

VGI Health Technology Annual Data
Trend
Other Current Receivables

VGI Health Technology Semi-Annual Data
Other Current Receivables

VGI Health Technology Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.


VGI Health Technology Other Current Receivables Related Terms

Thank you for viewing the detailed overview of VGI Health Technology's Other Current Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


VGI Health Technology (XNEC:VTL) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
19 Martin Place, Level 45, Suite 03, Sydney, NSW, AUS, 2003
VGI Health Technology Ltd develops and commercializes evidence-based nutraceuticals and pharmaceuticals. It has two evidence-based nutraceutical products ready for commercial launch in the US as well as a therapeutic drug development program. The nE1-Heart targets maintenance of heart health - tocotrienols have a similar mode of action (inhibition of HMCG CoA biosynthesis) as statins, the Gold Standard for treatment of hyperlipidaemia; and nE1-Eliteth that reduces Delayed Onset Muscle Soreness, improves muscle recovery after exercise, exercise endurance and maintenance of peak muscle power.

VGI Health Technology (XNEC:VTL) Headlines

No Headlines